GLAS Glass House Brands Inc. Annual reports only
Medicinal Chemicals & Botanical Products · NYSE · SEC CIK 1848731 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-9.4%
TTM net income YoY-5,814.6%
TTM EPS YoY-161.9%
Revenue 3-yr CAGR28.9%
Net income 3-yr CAGR—
Margins
Gross margin42.3%
Operating margin-9.1%
Net margin-16.3%
FCF margin-8.6%
EBITDA margin-0.8%
Returns
ROE-31.2%
ROA-9.4%
ROIC (approx.)-10.2%
Asset turnover0.58x
Leverage & solvency
Liabilities / assets45.2%
Debt / equity0.93x
Current ratio1.78x
Interest coverage-2.34x
Cash quality & payout
Operating cash flow / net income-0.39x
Accruals ratio-13.1%
Payout ratio—
Capex / revenue14.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $181.98M | $200.90M | $160.84M | $84.87M | $63.19M |
| Cost of revenue | $105.02M | $103.50M | $79.87M | $64.16M | $47.39M |
| Gross profit | $76.96M | $97.39M | $80.97M | $20.71M | $15.80M |
| SG&A expense | $64.10M | $60.13M | $52.91M | $45.57M | $33.78M |
| Operating income | -$16.53M | $5.74M | -$49.53M | -$56.39M | -$36.18M |
| Interest expense | $7.06M | $9.18M | $9.82M | $7.61M | $2.74M |
| Pretax income | -$17.02M | $11.22M | -$88.12M | -$37.35M | -$41.29M |
| Income tax | $11.93M | $10.50M | $9.94M | -$4.39M | $2.01M |
| Net income | -$29.66M | $519,000 | -$98.27M | -$32.90M | -$43.10M |
| EBITDA | -$1.53M | $20.04M | -$36.03M | -$45.07M | -$31.58M |
| EPS (basic) | -0.55 | -0.21 | -1.62 | -0.83 | -1.11 |
| EPS (diluted) | -0.55 | -0.21 | -1.62 | -0.83 | -1.11 |
| Weighted avg. shares (diluted) | 81.94M | 75.23M | 72.03M | 64.18M | 40.28M |
| Balance sheet | |||||
| Cash & equivalents | $23.35M | $36.92M | $32.52M | $14.14M | $54.07M |
| Receivables | $4.42M | $5.22M | $3.98M | $4.79M | $2.46M |
| Inventory | $26.23M | $14.25M | $8.84M | $10.95M | $6.53M |
| Current assets | $67.75M | $66.10M | $49.22M | $38.89M | $68.62M |
| PP&E, net | $228.76M | $212.25M | $215.69M | $216.43M | $195.80M |
| Goodwill | — | $0 | $0 | $37.80M | $4.92M |
| Intangibles | $11.58M | $14.20M | $21.21M | $35.92M | $5.63M |
| Total assets | $318.56M | $310.50M | $303.77M | $350.63M | $287.58M |
| Current liabilities | $37.96M | $66.48M | $87.36M | $54.00M | $55.24M |
| Short-term debt | $37,000 | $7.64M | $7.55M | $40,237 | $37,986 |
| Long-term debt | $68.63M | $50.55M | $56.51M | $62.62M | $44.82M |
| Total debt | $68.67M | $58.20M | $64.06M | $62.66M | $44.86M |
| Total liabilities | $143.96M | $146.45M | $158.54M | $129.49M | $105.65M |
| Shareholders' equity | $73.94M | $116.24M | $89.76M | $168.86M | $182.13M |
| Net debt | $45.32M | $21.27M | $31.54M | $48.51M | -$9.21M |
| Cash flow statement | |||||
| Operating cash flow | $11.45M | $28.39M | $23.22M | -$40.78M | -$20.29M |
| Capital expenditure | $27.18M | $10.29M | $12.31M | $27.77M | $108.50M |
| Free cash flow | -$15.73M | $18.10M | $10.91M | -$68.55M | -$128.78M |
| Investing cash flow | -$27.74M | -$10.29M | -$12.71M | -$29.20M | -$111.50M |
| Financing cash flow | $2.72M | -$13.70M | $7.87M | $30.06M | $181.32M |
| Depreciation & amortization | $15.00M | $14.30M | $13.50M | $11.32M | $4.60M |
| Stock-based compensation | $13.40M | $13.10M | $7.64M | $12.76M | $8.71M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.